It is already known from previous studies that GLP-1 RAs could improve liver damage and lipid metabolism in patients with liver disease by significantly reducing the fat content of the liver [163], even if the liver does not metabolize the GLP-1 RAs and therefore no dose modification is required in cirrhosis, in a liraglutide pharmacokinetic study [164]. The gene discussed is GCG; the disease is liver disorder.